Abeona Therapeutics
Tracked across 3 events · 18 articles · First seen Apr 02, 2026 · Last active Sep 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Abeona expands commercial footprint for ZEVASKYN by adding a large EB center as a QTC, potentially boosting sales.
Jul 21, 2026 · 6 articles
Regulatory
Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (Nasdaq: ABEO) concerning potential securities fraud or other unlawful business practices by the company and certain officers and/or directors. The investigation follows…
Impact: Abeona is the subject of the investigation. The company's stock dropped 14.95% after disclosing a revenue recognition shortfall for ZEVASKYN, and it now faces potential securities fraud claims.
Aug 27, 2026 · 6 articles
Regulatory
Impact: Abeona Therapeutics originally developed UX111 before transferring it to Ultragenyx for further development.
Apr 02, 2026 · 6 articles
100
Abeona Therapeutics disclosed revenue shortfallAbeona Therapeutics...
80
Pomerantz LLP launched investigation Abeona TherapeuticsAbeona Therapeutics...
ERGEN INTELLIGENCE
Track Abeona Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard